Guild Investment Management Inc. Grows Holdings in Novo Nordisk A/S $NVO

Key Points

• Guild Investment Management Inc. increased its holdings in Novo Nordisk A/S by 20.7%, bringing its total shares to 36,995, valued at approximately $2.55 million.
• Other institutional investors have also significantly increased their positions in Novo Nordisk, with Kingstone Capital Partners growing its stake by 301,443.6% to over 10 million shares.
• Novo Nordisk reported earnings of $0.97 per share, surpassing estimates, amidst a market capitalization of $263.90 billion, and the stock currently has a P/E ratio of 16.24.

Guild Investment Management Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 20.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,995 shares of the company's stock after buying an additional 6,345 shares during the quarter. Novo Nordisk A/S makes up about 2.2% of Guild Investment Management Inc.'s holdings, making the stock its 19th biggest holding. Guild Investment Management Inc.'s holdings in Novo Nordisk A/S were worth $2,553,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Kingstone Capital Partners Texas LLC grew its position in shares of Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock worth $690,560,000 after buying an additional 10,001,898 shares during the period. Nuveen LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $370,272,000. Amundi grew its position in shares of Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company's stock worth $331,576,000 after buying an additional 1,627,051 shares during the period. Acadian Asset Management LLC grew its position in shares of Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock worth $72,523,000 after buying an additional 1,038,137 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Novo Nordisk A/S by 118.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,594,544 shares of the company's stock worth $110,725,000 after buying an additional 864,579 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NVO opened at $59.10 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock has a market capitalization of $263.90 billion, a P/E ratio of 16.24, a P/E/G ratio of 2.66 and a beta of 0.68. The company's 50-day simple moving average is $54.84 and its two-hundred day simple moving average is $63.48. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $120.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. Morgan Stanley downgraded shares of Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and reduced their target price for the stock from $59.00 to $47.00 in a research report on Monday, September 29th. Hsbc Global Res upgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 1st. Weiss Ratings reiterated a "hold (c-)" rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Rothschild Redb upgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Finally, HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $77.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.